Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5184346
Max Phase: Preclinical
Molecular Formula: C16H14N2O5S
Molecular Weight: 346.36
Associated Items:
ID: ALA5184346
Max Phase: Preclinical
Molecular Formula: C16H14N2O5S
Molecular Weight: 346.36
Associated Items:
Canonical SMILES: COc1ccccc1CNC(=O)N1C(=O)c2ccccc2S1(=O)=O
Standard InChI: InChI=1S/C16H14N2O5S/c1-23-13-8-4-2-6-11(13)10-17-16(20)18-15(19)12-7-3-5-9-14(12)24(18,21)22/h2-9H,10H2,1H3,(H,17,20)
Standard InChI Key: REOVDRBXAOLCDP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 346.36 | Molecular Weight (Monoisotopic): 346.0623 | AlogP: 1.75 | #Rotatable Bonds: 3 |
Polar Surface Area: 92.78 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.65 | CX Basic pKa: | CX LogP: 1.89 | CX LogD: 1.89 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.91 | Np Likeness Score: -1.12 |
1. Wen W, Cao H, Xu Y, Ren Y, Rao L, Shao X, Chen H, Wu L, Liu J, Su C, Peng C, Huang Y, Wan J.. (2022) N-Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction., 65 (13.0): [PMID:35786925] [10.1021/acs.jmedchem.2c00336] |
Source(1):